Credit Suisse’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-126,229
| Closed | -$2.74M | – | 4329 |
|
|
2017
Q2 | $2.74M | Buy |
126,229
+94,039
| +292% | +$1.71M | ﹤0.01% | 2020 |
|
|
2017
Q1 | $452K | Sell |
32,190
-19,317
| -38% | -$316K | ﹤0.01% | 3354 |
|
|
2016
Q4 | $966K | Sell |
51,507
-55,266
| -52% | -$939K | ﹤0.01% | 3050 |
|
|
2016
Q3 | $1.76M | Buy |
106,773
+70,976
| +198% | +$1.05M | ﹤0.01% | 2472 |
|
|
2016
Q2 | $481K | Buy |
35,797
+21,012
| +142% | +$307K | ﹤0.01% | 3449 |
|
|
2016
Q1 | $226K | Sell |
14,785
-42,784
| -74% | -$671K | ﹤0.01% | 3641 |
|
|
2015
Q4 | $1.14M | Buy |
57,569
+39,642
| +221% | +$753K | ﹤0.01% | 2713 |
|
|
2015
Q3 | $313K | Sell |
17,927
-115,467
| -87% | -$2.35M | ﹤0.01% | 3690 |
|
|
2015
Q2 | $2.7M | Buy |
133,394
+85,518
| +179% | +$1.65M | ﹤0.01% | 2303 |
|
|
2015
Q1 | $843K | Sell |
47,876
-7,595
| -14% | -$129K | ﹤0.01% | 3131 |
|
|
2014
Q4 | $904K | Buy |
55,471
+27,091
| +95% | +$497K | ﹤0.01% | 3225 |
|
|
2014
Q3 | $627K | Sell |
28,380
-13,771
| -33% | -$282K | ﹤0.01% | 3463 |
|
|
2014
Q2 | $849K | Sell |
42,151
-12,956
| -24% | -$219K | ﹤0.01% | 3428 |
|
|
2014
Q1 | $1.02M | Sell |
55,107
-179,187
| -76% | -$2.47M | ﹤0.01% | 3099 |
|
|
2013
Q4 | $2.36M | Buy |
234,294
+161,514
| +222% | +$1.95M | ﹤0.01% | 2524 |
|
|
2013
Q3 | $938K | Buy |
72,780
+8,017
| +12% | +$98.6K | ﹤0.01% | 3017 |
|
|
2013
Q2 | $769K | Buy |
+64,763
| New | +$702K | ﹤0.01% | 2999 |
|
Other funds holding AMRI
Credit Suisse's AMRI Position: Q3 2017 in Review
Credit Suisse sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 126,229 shares — an estimated $2.74M sold.
Credit Suisse first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.74M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Credit Suisse reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Credit Suisse sold 126,229 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.74M.
- Credit Suisse first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Credit Suisse's Albany Molecular Research Inc position peaked at $2.74M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Credit Suisse's 13F filing for Q3 2017, filed 14 Nov 2017.